Health TrialsbyHealthPanel

HIV Self-Testing and Long-Acting Injectables for HIV Treatment and Prevention Among Commercial Minibus Drivers (I-TEST LAIs) in Nigeria

ConditionHIV
Trial statusNot yet recruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexMale
Age18+
SponsorGeorge Washington University

About this trial

Long-acting injectable antiretroviral therapy (LAI ART) and Pre-Exposure Prophylaxis (LAI PrEP) have the potential to transform HIV treatment and prevention, especially in reaching individuals such as commercial minibus drivers who have minimal or no contact with traditional health facilities. The project proposes to use a culturally appropriate and community-engaged approach to promote the uptake of HIV self-testing, LAI-ART, and LAI-PrEP among commercial minibus drivers in Nigeria by engaging commercial minibus drivers as peer educators/research facilitators.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Male commercial minibus drivers who have worked as a driver for at least 6 months

18 years old or older

Currently and planning on residing in one of the LGAs during the next 12 months

Owning a mobile phone

Disqualifiers

Known HIV positivity

Not ability to provide informed consent3

No access to a cell phone

Trial design

Design model

Parallel

Treatments tested in this trial

  • ITEST-LAI

    Behavioral

    The ITEST-LAI intervention includes male peer-led HIVST distribution and promotion, linkage to male-friendly clinics for confirmatory testing and follow-up care, peer support and technical assistance to address implementation challenges, and continuous monitoring and feedback for male peer educators and research facilitators (MPERFs).

Treatment groups

400 Participants
are divided into 2 treatment groups
Group A: I-TEST LAI Intervention:Experimental treatment 1 intervention
Group B: Standard of CareNo intervention 0 interventions

Trial outcomes

Primary outcomes

1

ART or PrEP Initiation

Use of patient records and self-report to determine initiation of HIV treatment or preventive medications.

Time frame
Baseline and follow-up surveys at 6-,12-, 18-, and 24 months

Secondary outcomes

1

HIV Testing

Use of patient records and self-report to determine HIV testing behavior (including use of HIVST and confirmatory testing in clinics).

Time frame
Baseline and follow-up surveys at 6-,12-, 18-, and 24-months
2

ART Adherence

Use of self-report and hair sample to measure medication adherence.

Time frame
Baseline and follow-up surveys at 6-,12-, 18-, and 24-months
3

PrEP Adherence

Use of hair samples and self-report to measure medication adherence.

Time frame
Baseline and follow-up surveys at 6-,12-, 18-, and 24-months
4

Viral Load Supression

Use of blood samples to measure viral load suppression among those who received an HIV diagnosis.

Time frame
Baseline and follow-up surveys at 6-,12-, 18-, and 24-months

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

George Washington University

Lead sponsor

The George Washington University Milken Institute School of Public Health (GWU)

Collaborator

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: